Cellect Biotechnology logo

APOP - Cellect Biotechnology News Story

$3.17 0.0  0.3%

Last Trade - 22/01/21

Sector
Healthcare
Size
Micro Cap
Market Cap £5.28m
Enterprise Value £805k
Revenue £n/a
Position in Universe 6152nd / 6630

BUZZ-Cellect Biotechnology: Rises on starting U.S. clinical trial of ApoGraft

Thu 22nd October, 2020 3:56pm
** Shares of Israel-based stem cell therapy co  APOP.O  rise
2.2% to $2.11
    ** Co initiates clinical trial in the U.S. to determine
safety and tolerability of its ApoGraft technology for bone
marrow transplantations  urn:newsml:reuters.com:*:nGNX64VRND
    ** APOP says ApoGraft cell-selection technology is designed
to prevent graft-versus-host disease, an immune condition that
occurs after bone marrow transplantation
    ** Co says first trial of ApoGraft in Israel had enrolled 11
patients, while the U.S. trial will have 18 
    ** APOP shares down 4.66% YTD

 (Reporting by Lasya Priya M in Bengaluru)
 ((LasyaPriya.M@thomsonreuters.com;))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.